Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals
- 1 November 2010
- journal article
- clinical trial
- Published by SAGE Publications in Antiviral Therapy
- Vol. 15 (8) , 1107-1114
- https://doi.org/10.3851/imp1673
Abstract
Background: Atazanavir plus raltegravir 300/400 mg twice daily is being explored as a ritonavir- and nucleoside- sparing treatment strategy. The pharmaco-kinetics and safety of this combination in healthy individuals were evaluated. Methods: A total of 22 healthy individuals received raltegravir 400 mg on days 1–5, atazanavir 300 mg on days 6–12 and atazanavir plus raltegravir 300/400 mg on days 13–26, twice daily with a light meal. Serial blood samples were collected 12 h after the morning dose on days 5, 12 and 26; safety assessments, clinical laboratory data and serial electrocardiograms (ECGs) at 0, 2 and 6 h were obtained. Results: Raltegravir coadministration reduced atazanavir geometric mean maximum plasma concentration (Cmax), area under the plasma concentration–time curve from 0 to 12 h post-dose (AUC0–12) and trough plasma concentration (Cmin) by 11%, 17% and 29%, respectively, compared with atazanavir alone. Geometric mean atazanavir Cmin was 817 ng/ml (range 250–1,550) with raltegravir coadministration. Atazanavir increased raltegravir geometric mean Cmax, AUC0–12 and Cmin by 39%, 54% and 48%, respectively. All adverse events were of mild or moderate intensity. Hyperbilirubinaemia and ECG PR increases with atazanavir were similar to those of atazanavir/ritonavir once daily. No corrected QT prolongations were noted. Mean QRS increase from baseline was 11.0 ms (range 2–25) after receiving atazanavir for 7 days; no further QRS increase was noted and no QRS interval was >120 ms with raltegravir coadministration. No ECG changes were observed with raltegravir alone. Conclusions: Coadministration of atazanavir and raltegravir 300/400 mg twice daily decreased atazanavir AUC0–12 and Cmin relative to atazanavir alone, and increased AUC0–12 of raltegravir relative to raltegravir alone. Atazanavir and raltegravir alone and coadministered appeared safe and well-tolerated.Keywords
This publication has 19 references indexed in Scilit:
- Atazanavir Modestly Increases Plasma Levels of Raltegravir in Healthy SubjectsClinical Infectious Diseases, 2008
- Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected personsCurrent Opinion in HIV and AIDS, 2008
- Reduced bone mineral density in HIV-infected patients: prevalence and associated factorsAIDS, 2008
- Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid–liquid extraction and HPLC-MS/MSJournal of Chromatography B, 2007
- Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase EnzymeDrug Metabolism and Disposition, 2007
- Treatment strategies for HIV lipodystrophyCurrent Opinion in HIV and AIDS, 2007
- Tenofovir-Associated Acute and Chronic Kidney Disease: A Case of Multiple Drug InteractionsClinical Infectious Diseases, 2006
- IN VITRO INHIBITION OF UDP GLUCURONOSYLTRANSFERASES BY ATAZANAVIR AND OTHER HIV PROTEASE INHIBITORS AND THE RELATIONSHIP OF THIS PROPERTY TO IN VIVO BILIRUBIN GLUCURONIDATIONDrug Metabolism and Disposition, 2005
- Tenofovir‐Related Nephrotoxicity in Human Immunodeficiency Virus–Infected Patients: Three Cases of Renal Failure, Fanconi Syndrome, and Nephrogenic Diabetes InsipidusClinical Infectious Diseases, 2003
- Changes in parietal cell structure and function in HIV diseaseDigestive Diseases and Sciences, 1996